Clinical implications of lower urinary tract pharmacology.
D000317:Adrenergic alpha-Antagonists / Q000494:pharmacology; D000319:Adrenergic beta-Antagonists / Q000494:pharmacology; D000818:Animals; D001626:Bethanechol Compounds / Q000494:pharmacology; D001971:Bromocriptine / Q000494:pharmacology / Q000627:therapeutic use; D006801:Humans; D010276:Parasympatholytics / Q000494:pharmacology / Q000627:therapeutic use; D011388:Prolactin / Q000494:pharmacology; D011453:Prostaglandins / Q000494:pharmacology; D013566:Sympathomimetics / Q000494:pharmacology; D001743:Urinary Bladder / Q000187:drug effects; D014549:Urinary Incontinence / Q000188:drug therapy; D014551:Urinary Tract / Q000187:drug effects*
D000317:Adrenergic alpha-Antagonists; D000319:Adrenergic beta-Antagonists; D001626:Bethanechol Compounds; D010276:Parasympatholytics; D011453:Prostaglandins; D013566:Sympathomimetics; D001971:Bromocriptine; D011388:Prolactin